openFDA
Cure8 regulatory brief
Why This Matters
An official FDA/DailyMed label update for tofacitinib reiterates indications (including ulcerative colitis) and emphasizes a boxed warning about infections, mortality, malignancy, cardiovascular events, and thrombosis that could affect people with IBD and their treatment choices.
Who Should Pay Attention
Adults with ulcerative colitis or other IBD on or considering tofacitinib, clinicians prescribing JAK inhibitors, and caregivers of immunosuppressed patients.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The source is an FDA DailyMed drug label update for tofacitinib (a JAK inhibitor). The label lists approved indications (including ulcerative colitis) and the boxed warning that highlights serious infections, increased mortality in certain RA patients, malignancy risk, major adverse cardiovascular events, and thrombosis.
It also states limitations on combining tofacitinib with biologic therapies or potent immunosuppressants. The label update is a regulatory record: it reports official prescribing information and safety warnings rather than study results or patient advice. Read the full label for dosing, monitoring, and specific contraindications.
If you take tofacitinib or are considering it, discuss the updated boxed warning and treatment limitations with your clinician, especially if you have cardiovascular risk factors, a history of recurrent infections, or are on other immunosuppressants.
Keep In Mind
DailyMed is the official source of prescribing information; this is a regulatory-label document, not a research report. Discuss label changes with your clinician for how they apply to your situation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorXLCare Pharmaceuticals Inc
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedNov 2, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tofacitinib FDA label update (2026-09-01)
This FDA drug-label update describes approved uses and safety warnings for tofacitinib, a JAK inhibitor used in immune-mediated diseases including ulcerative colitis. The boxed warnings highlight serious infection and...
Tofacitinib FDA label update (2026-07-27)
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
Tofacitinib FDA label update (2026-08-13)
The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...